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Introduction: The primary objective of this study was to deter-
mine the prognostic signiﬁcance of computed tomography (CT)-
determined sarcopenia in small-cell lung cancer (SCLC) patients.
Methods: This retrospective study consisted of a total of 149 con-
secutive SCLC patients. The cross-sectional area of muscle at the 
level of the third lumbar vertebra (L3) was measured using base-
line CT images. Sarcopenia was deﬁned as a L3 muscle index of 
less than 55 cm2/m2 for men and of less than 39 cm2/m2 for women 
as proposed by international consensus of cancer cachexia. In 
addition, Korean-speciﬁc cutoffs for sarcopenia was also applied 
(49 cm2/m2 for men and 31 cm2/m2 for women). Overall survival 
(OS) and clinical characteristics of patients with or without sarco-
penia were compared.
Results: Mean patient age was 68.6 ± 9.5 years. Most were male 
(85.3%) and 67.8% had extensive disease at time of diagnosis. 
Sarcopenia was present in 118 patients (79.2%) and was signiﬁ-
cantly related to an advanced age (p = 0.028), male sex (p < 0.001), 
lower body mass index (p < 0.001), and poor performance status 
(p = 0.049). Sarcopenic patients had shorter OS than nonsarcope-
nic patients (median: 8.6 months versus 16.8 months; p = 0.031). 
Multivariable analysis revealed that sarcopenia was an independent 
prognostic factor of poor survival (hazards ratio: 1.68; 95% conﬁ-
dence interval: 1.04–2.72; p = 0.034), along with extensive stage 
(p < 0.001), supportive care only (p < 0.001), and an elevated lactate 
dehydrogenase level (p = 0.020). Using Korean sarcopenia cutoffs, 
sarcopenic patients were also found to have poorer OS than nonsar-
copenic patients, however, the survival difference was not statisti-
cally signiﬁcant (median: 8.4 months versus 12.7 months; p = 0.144 
by the log-rank test).
Conclusions: Sarcopenia as determined by CT could be used to 
predict prognosis in patients with SCLC. Optimum reference values 
to predict cancer-speciﬁc outcomes should be tailored by further 
studies.
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Lung cancer is the leading cause of cancer death worldwide and small-cell lung cancer (SCLC) accounts for about 15% 
of all cases.1,2 SCLC grows rapidly and most patients present 
with disseminated disease at the time of diagnosis. Although 
SCLC is highly responsive to initial chemotherapy and radio-
therapy, its prognosis is poor; median survival durations are 
only 15 to 20 months for limited stage and 8 to 13 months for 
extensive stage.3,4
Clinical outcomes depend not only on tumor-related fac-
tors, such as disease extent, but also on host factors, such as 
performance status (PS) and weight loss.5 Weight loss, which 
is a key diagnostic criterion for cancer cachexia, is common at 
presentation in patients with SCLC. However, it may be mis-
leading sometimes as the evaluation of body weight change 
depends on patient response during a medical examination.6 
In addition, body weight change does not precisely reflect 
body composition change, and weight loss is uncertain in 
patients with a large tumor mass or fluid collection, such as 
pleural effusion or body edema.
Loss of muscle mass is an important age-related health 
implication in older persons, and because sarcopenia is a 
modiﬁable factor associated with physical disability, inju-
ries, and mortality, it is important that the status of muscle 
mass be recognized. In addition, the clinical importance of 
sarcopenia is being increasingly recognized as a component 
of cancer cachexia syndrome.7 The prognostic signiﬁcance 
of sarcopenia has been revealed for several cancers, such as 
breast cancer, hepatocellular carcinoma, and advanced uro-
thelial cancer, because the status is associated with functional 
impairment, increased risk of chemotherapy-related toxici-
ties, and reduced survival.8–13 Given this increasing recogni-
tion, a recent international consensus established sarcopenia 
as a key diagnostic criterion for cancer cachexia.14 However, 
few studies have addressed the prognostic signiﬁcance of 
CT-determined sarcopenia in SCLC patients. Accordingly, 
the primary objective of this study was to determine the 
prognostic signiﬁcance of sarcopenia as assessed by base-
line CT in SCLC.
DOI: 10.1097/JTO.0000000000000690
Copyright © 2015 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/15/1012-1795
Prognostic Significance of CT-Determined Sarcopenia  
in Patients with Small-Cell Lung Cancer
Eun Young Kim, MD,* Young Saing Kim, MD,† Inkeun Park, MD,† Hee Kyung Ahn, MD,†  
Eun Kyung Cho, MD,† and Yu Mi Jeong, MD*
*Department of Radiology, and †Division of Hematology and Oncology, 
Department of Internal Medicine, Gachon University Gil Hospital, 
Incheon, Republic of Korea.
All authors participated in the concept/design, data interpretation, drafting, 
and critical revision of the article. The statistical analysis was conducted 
by Young Saing Kim.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Young Saing Kim, MD, Division of Hematology 
and Oncology, Department of Internal Medicine, Gachon University Gil 
Medical Center, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, 
Republic of Korea. E-mail:zoomboom@hanmail.net
ORIGINAL ARTICLE
1796 Copyright © 2015 by the International Association for the Study of Lung Cancer
Kim et al. Journal of Thoracic Oncology ® • Volume 10, Number 12, December 2015
PATIENTS AND METHODS
Patients
The radiology database and medical records system at 
Gachon University Gil Medical Center (Incheon, Korea) were 
searched for patients with newly diagnosed, pathologically 
proven SCLC that underwent a whole body PET/CT scan 
from January 2010 to November of 2014.
Height and weight were measured and functional status 
was recorded at ﬁrst visit to our oncology department. Body 
mass index (BMI) was deﬁned as weight divided by height 
squared (kg/m2), and BMI values were categorized as under-
weight (less than 18.5 kg/m2), normal (18.5–22.9 kg/m2), over-
weight (23.0–24.9 kg/m2), or obese (greater than or equal to 
25 kg/m2).15
SCLC was classiﬁed using two stages, that is, as lim-
ited or extensive. Limited stage was deﬁned as American 
Joint Committee on Cancer stages I to III, which can be safely 
treated by deﬁnitive radiation therapy.16 Treatment for SCLC 
included active therapies, such as chemotherapy, chemora-
diotherapy (including sequential and concurrent therapy), 
chest radiotherapy, and supportive care only. The institutional 
review board of our hospital approved this retrospective study 
and waived the requirement for informed patient consent.
PET/CT
All patients fasted for at least 6 hours before PET/CT to 
ensure a normal blood glucose level. About 60 minutes after 
the intravenous administration of 370 MBq (10 mCi) of FDG, 
imaging was performed using an integrated PET/CT device 
(Siemens Medical Systems, Erlangen, Germany), equipped 
with lutetium oxyorthosilicate crystal PET detectors, and six 
slices of CT detectors.
CT imaging was performed from the head to the pel-
vic floor without contrast administration using the following 
parameters: 130 kVp, 110 mAs, 2-mm pitch, 1-second tube 
rotation, and a slice thickness of 5 mm, which matched the 
section thickness of PET images. Subsequent PET scanning 
was performed using ﬁve to eight table positions for adequate 
coverage from head to pelvic floor. CT data were used for 
attenuation correction and PET image data were reconstructed 
using an ordered set expectation maximization algorithm.
Image Analysis
CT images of whole body PET/CT scans obtained at the 
time of diagnosis were retrospectively analyzed by a subspe-
cialty-trained chest radiologist. The third lumbar vertebra (L3) 
was selected as a landmark since the cross-sectional area of 
tissues in this region provide an established means of estimat-
ing total body tissue quantities in the general population. This 
technique has reported Pearson correlation coefﬁcients rang-
ing from 0.71 to 0.92.17,18 Two consecutive CT images extend-
ing from L3 in the inferior direction were assessed.
Body composition analyses were performed using 
commercially available software (Terarecon 3.4.2.11, San 
Mateo, CA). Tissue cross-sectional areas (cm2) of respective 
tissues in slices were computed automatically by summing 
appropriate pixels. The CT Hounsﬁeld unit (HU) ranges used 
for speciﬁc tissues were −29 to 150 HU for skeletal muscle and 
−190 to −30 HU for adipose tissue. After applying threshold 
methods using a predeﬁned HU threshold set for each slice, 
boundaries between different tissues were corrected manually 
when necessary. L3 muscle index (cm2/m2) was deﬁned as the 
cross-sectional area of muscle at the L3 level normalized for 
stature as is conventional for BMI.
Definition of Sarcopenia
Sarcopenia was deﬁned as a L3 muscle index of less than 
55 cm2/m2 for men and of less than 39 cm2/m2 for women, as pro-
posed by international consensus of cancer cachexia.14 In addi-
tion, we subsequently analyzed the prevalence and prognostic 
signiﬁcance of sarcopenia using Korean-speciﬁc cutoffs for 
sarcopenia. A previous epidemiologic study evaluated height-
adjusted appendicular skeletal muscle mass (ASM; kg/m2) 
of a young reference group of Koreans using dual energy 
X-ray absorptiometry (DXA), and determined sarcopenia cut-
off values for Korean men and women of 6.58 and 4.59 kg/m2, 
respectively.19 A previous study18 showed that L3 muscle area 
by CT and ASM by DXA are linearly related by the regression 
equation:
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We used this equation to calculate corresponding 
L3 muscle index cutoff values of 49 cm2/m2 for men and 
31 cm2/m2 for women.
Statistical Analysis
Descriptive statistics are reported as proportions or 
means with standard deviations. For categorical variables, 
comparisons between subjects with and without sarcope-
nia were performed using Pearson’s χ2 test or Fisher’s exact 
test. Continuous variables were compared using the Student’s 
t test or the Mann–Whitney U test. Survivals were estimated 
using the Kaplan–Meier method and survivals were compared 
using the log-rank test. Overall survival (OS) was estimated 
from date of baseline PET/CT to death or last follow-up. 
Univariable and multivariable Cox proportional hazard 
models were used to identify prognostic factors of survival. 
Variables with a p value of less than 0.15 by the log-rank 
test were included in the multivariable analysis. Two-sided 
p  values of less than 0.05 were considered statistically sig-
niﬁcant. The analysis was performed using SPSS for Windows 
ver. 19.0 (SPSS Inc., Chicago, IL).
RESULTS
Characteristics of the Study Population
A total of 149 consecutive patients were included in 
this study (Table 1). Mean patient age was 68.6 ± 9.5 years 
and 127 (85.2%) were male. Of the 149 patients, 101 (67.8%) 
had extensive disease at ﬁrst presentation, and 31 patients 
(20.8%) received supportive care only. Average BMI was 
22.1 ± 3.5 kg/m2 and 16.1% of the patients were underweight 
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(n = 24). Mean L3 muscle index was 47.9 ± 9.7 cm2/m2 (range: 
25.4–111.7 cm2/m2) for men and 41.6 ± 7.0 cm2/m2 (range: 
28.3–56.0 cm2/m2) for women.
Prevalence of and factors 
Associated with Sarcopenia
The overall prevalence of sarcopenia was 79.2% (87.4% 
for men and 36.4% for women). In elderly patients (greater 
than or equal to 65 years old), the overall prevalence of sar-
copenia was 83.0% (90.4% for men and 47.1% for women). 
The clinical characteristics of patients with or without sarco-
penia are summarized in Table 1. Sarcopenia was found to be 
signiﬁcantly associated with advanced age (p = 0.028), a male 
sex (p < 0.001), poor PS (p = 0.049), and lower BMI (p < 
0.001). No signiﬁcant difference was found between patients 
with or without sarcopenia in terms of smoking history, stage, 
comorbidity index, treatment, or serum lactate dehydrogenase 
(LDH greater than or equal to 486 U/L).
Prognostic Significance of 
Sarcopenia in SCLC Patients
Over a median follow-up of 29.0 months (95% conﬁ-
dence interval [CI]: 19.7–38.3 months), 123 patients (82.6%) 
died. For all 149 patients, median OS was 9.6 months (95% 
TABLE 1. Characteristics of Patients with Small-Cell Lung Cancer According to the Presence of Sarcopenia
Characteristics All (n = 149) Sarcopenia (n = 118) No Sarcopenia (n = 31) p
Age (years) 68.6 ± 9.5 69.4 ± 9.6 65.2 ± 8.5 0.028a
  ≥ 65 years 100 (67.1%) 83 (70.3%) 17 (54.8%) 0.102b
Male 127 (85.2%) 110 (93.2%) 17 (54.8%) <0.001b
Smoking status
  Current/ex-smoker 130 (87.2%) 106 (89.8%) 24 (77.4%) 0.075c
  Never smoker 19 (12.8%) 12 (10.2%) 7 (22.6%)
Pack year, median (range) 38 (0–171) 40 (0–171) 30 (0–70) 0.053d
Stage
  Limited disease 48 (32.2%) 36 (30.5%) 12 (38.7%) 0.385b
  Extensive disease 101 (67.8%) 82 (69.5%) 19 (61.3%)
ECOG PS
  0–1 109 (73.2%) 82 (69.5%) 27 (87.1%) 0.049b
  ≥2 40 (26.8%) 36 (30.5%) 4 (12.9%)
Charlson comorbidity index
  0 47 (31.5%) 39 (33.1%) 8 (25.8%) 0.489b
  1–2 78 (52.4%) 62 (52.5%) 16 (51.6%)
  ≥3 24 (16.1%) 17 (14.4%) 7 (22.6%)
Body mass index (kg/m2) 22.1 ± 3.5 21.3 ± 3.1 25.2. ± 3.4 <0.001a
  Underweight 24 (16.1%) 23 (19.5%) 1 (3.2%) <0.001b
  Normal weight 64 (43.0%) 58 (49.2%) 6 (19.4%)
  Overweight 31 (20.8%) 24 (20.3%) 7 (22.6%)
  Obesity 30 (20.1%) 13 (11.0%) 17 (54.8%)
Treatment
  Chemotherapy 72 (48.3%) 56 (47.5%) 16 (51.6%) 0.521b
  Chemoradiotherapy 44 (29.5%) 33 (28.0%) 11 (35.5%)
  Chest radiotherapy 2 (1.3%) 2 (1.7%) 0
  Supportive care only 31 (20.8%) 27 (22.9%) 4 (12.9%)
First-line chemotherapy regimen
  Etoposide/cisplatin 86 (74.1%) 65 (73.0%) 21 (77.8%) 0.617b
  Etoposide/carboplatin 14 (12.1%) 10 (11.2%) 4 (14.8%)
  Irinotecan/cisplatin 12 (10.3%) 10 (11.2%) 2 (7.4%)
  Etoposide monotherapy 4 (3.4%) 4 (4.5%) 0
LDH (U/L), median (range) 529 (282–8587) 534 (282–8587) 495 (359–1582) 0.840d
  Elevated LDH (≥486 U/L) 83 (59.7%) 74 (62.7%) 19 (61.3%) 0.884b
Values are means ± standard deviations.
aStudent t test.
bχ2 test.
cFisher’s exact test.
dMann–Whitney U test.
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.
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CI: 7.2–11.9 months). Furthermore, patients with sarcope-
nia had a signiﬁcantly shorter median OS than those without 
(8.6 versus 16.8 months; p = 0.031 by the log-rank test; Fig. 1).
Univariable analysis showed that in addition to the pres-
ence of sarcopenia, advanced age (greater than or equal to 
65 years), extensive disease, poor PS, supportive care only, 
and elevated LDH were poor prognostic factors (Table 2). 
Multivariable analysis showed that sarcopenia was an inde-
pendent prognostic factor for shorter OS (hazard ratio [HR]: 
1.68; 95% CI: 1.04–2.72; p = 0.034), along with extensive 
disease (HR: 2.29; 95% CI: 1.47–3.57; p < 0.001), supportive 
care only (HR: 6.69; 95% CI: 3.75–11.92; p < 0.001), and 
elevated LDH (HR: 1.60; 95% CI: 1.08–2.37; p = 0.020).
In the subsequent analysis conducted using Korean-
speciﬁc sarcopenia cutoffs (49 cm2/m2 for men and 31 cm2/m2  
for women), the overall prevalence of sarcopenia reduced 
79.2% to 53.0% (87.4% to 60.6% for men, and 36.4% to 
13.6% for women) in SCLC patients. In elderly patients, the 
overall prevalence of sarcopenia was 58.0% (66.3% for men 
and 17.6% for women). Using these lower cutoffs, sarcopenic 
patients had a shorter OS than nonsarcopenic patients but the 
survival difference was not statistically signiﬁcant (median 8.4 
months versus 12.7 months; p = 0.144 by the log-rank test). 
Extensive disease (HR: 2.25; 95% CI: 1.44–3.51; p < 0.001) 
and supportive care only (HR: 7.08; 95% CI: 3.96–12.65; 
p < 0.001) remained independent prognostic factors by mul-
tivariable analysis; sarcopenia (p = 0.284), advanced age 
(p = 0.078), poor PS (p = 0.098), and elevated LDH 
(p = 0.058) were not found to be independently signiﬁcant.
DISCUSSION
Sarcopenia was originally described in elderly individu-
als without cancer by Rosenberg in 1989.20 Elderly people 
are highly susceptible to sarcopenia, which may be associ-
ated with muscle weakness, falls, fractures, activity limita-
tions, and an increased risk of death. Sarcopenia is also an 
adverse effector in cancer patients, because it is associated 
with poor physical function, intolerance of anticancer therapy, 
and reduced survival.8–13 Since the reference points used to 
deﬁne sarcopenia in epidemiologic studies are based on the 
skeletal muscle mass of healthy young reference group, the 
cutoffs used inevitably have ethnic and gender-speciﬁc char-
acteristics.21 Furthermore, most epidemiologic studies have 
determined the prevalence of sarcopenia using cutoff values 
determined by DXA; height-adjusted ASM (kg/m2).19,21 Few 
have been incorporated CT into routine assessment of sarco-
penia for the cancer patients, and the prognostic signiﬁcance 
of CT-determined sarcopenia has rarely been assessed. In 
this study, we assessed prognostic signiﬁcance of sarcopenia 
determined by CT using two different sets of cutoffs in SCLC 
patients. When the cutoffs proposed by international consen-
sus of cancer cachexia14 were used, we found sarcopenia was 
an independent prognostic factor in SCLC patients even after 
adjusting for known prognostic factors, such as PS, LDH, 
tumor stage, age, and supportive care only.
fIGURE 1. Kaplan–Meier estimates of overall survival in 
patients with or without sarcopenia (sarcopenia was defined 
as a L3 muscle index of less than 55 cm2/m2 for men and of 
less than 39 cm2/m2 for women). Patients with sarcopenia 
had a significantly shorter OS than those without (median OS 
8.6 versus 16.8 months; p = 0.031 by the log-rank test).
TABLE 2. Results of Univariable and Multivariable Analyses of Overall Survival
Variables
Univariable Analysis Multivariable Analysis
HR (95% CI) pa HR (95% CI) p
Male sex 1.03 (0.61–1.72) 0.923
Age ≥ 65 years 2.03 (1.36–3.01) <0.001 1.46 (0.95–2.24) 0.086
Extensive stage 2.82 (1.85–4.29) <0.001 2.29 (1.47–3.57) <0.001
ECOG PS ≥ 2 3.08 (2.08–4.57) <0.001 1.48 (0.95–2.31) 0.087
Supportive care only 11.28 (6.51–19.53) <0.001 6.69 (3.75–11.92) <0.001
Sarcopenia 1.66 (1.04–2.63) 0.031 1.68 (1.04–2.72) 0.034
BMI < 23 kg/m2 1.19 (0.83–1.72) 0.340
Charlson comorbidity index ≥ 1 1.32 (0.89–2.00) 0.166
Current/ex-smoker 1.29 (0.74–2.25) 0.370
Elevated LDH (≥ 486 U/L) 1.70 (1.16–2.48) 0.006 1.60 (1.08–2.37) 0.020
aLog-rank test.
HR, hazard ratio; CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; BMI, body mass index; LDH, lactate dehydrogenase.
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Sarcopenia is known to be associated with frailty and 
increased catabolism,9–13 and in SCLC, sarcopenia is signiﬁ-
cantly associated with poor PS (indicator of frailty), and lower 
BMI (indicator of catabolism). Although we found poor PS and 
lower BMI were related to sarcopenia, they were not indepen-
dent prognostic indicators in the present study, which suggests 
that sarcopenia surpasses these factors as a prognostic effector. 
Furthermore, 60.7% of overweight or obese patients were sar-
copenic, which indicates BMI alone is an inadequate measure 
of body composition and underlines the importance of assess-
ing sarcopenia as a key diagnostic criterion for cancer cachexia.
However, when we applied the ethnic speciﬁc cutoffs for 
sarcopenia,19 its prevalence decreased from 79.2% to 53.0% 
and its prognostic signiﬁcance disappeared. These ﬁndings sug-
gest different sarcopenia cutoffs from general population need 
to be applied to cancer patients to determine prognosis and that 
optimum reference values be used to predict cancer-speciﬁc 
outcomes. Despite increasing recognition of the importance 
of sarcopenia for cancer patients, it is clear that the modalities 
and cutoffs used in current clinical practice to evaluate skeletal 
muscle reduction in oncology patients vary considerably, and 
that as a result, the implications of conclusions also vary.7
A recent epidemiologic study reported prevalence of sar-
copenia of 12.4% for men and 0.1% for women in an elderly 
Korean general population (greater than or equal to 65 years).19 
The higher prevalence of sarcopenia in this study (66.3% and 
17.6% for elderly men and women, respectively, with SCLC 
using the same cutoffs) was probably due to cancer-related pro-
cesses, genetic predispositions, and lifestyle factors.
In this study, we evaluated sarcopenic status using CT 
images taken at time of SCLC diagnosis. Since all patients 
underwent whole body PET/CT imaging for diagnosis and stag-
ing at initial work-up, we used integrated noncontrast CT images 
obtained during the PET/CT examination. The presence of sar-
copenia can be determined by secondary analysis of CT images 
without additional cost or radiation exposure. Furthermore, CT 
is regarded as the gold standard method for determining body 
composition because it differentiates fat and other soft tissues, 
and because it provides a means of quantifying tissue’s cross-
sectional area at the L3 level, which are known to be strongly 
correlated with whole body muscle mass and fat mass.22
Because sarcopenia is a complex multifactorial condi-
tion, a comprehensive multidimensional approach using phar-
macologic agents and nonpharmacologic interventions, such 
as exercise and nutritional supplements, is more likely to be 
effective at reversing and stabilizing the muscle wasting pro-
cess.6 Recently, a better understanding of the molecular and 
cellular bases of sarcopenia has resulted from efforts to iden-
tify novel drug targets and to develop better biomarkers for 
monitoring therapeutic efﬁcacy.23 Nonetheless, further studies 
are required to investigate how such therapeutic interventions 
reverse muscle wasting and improve outcomes in SCLC.
In conclusion, sarcopenia, as determined by CT, can be 
used to predict prognosis in SCLC patients. The identiﬁca-
tion of sarcopenia in SCLC patients might aid the selection of 
an optimal anticancer treatment and enable early intervention 
to maintain muscle mass and improve prognosis. Additional 
studies are required to determine optimum reference values 
for predicting cancer-speciﬁc outcomes.
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